Diabetes drug metformin inhibits multidrug-resistant breast cancer

December 6, 2017, Public Library of Science

The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it¹s appeared, according to a study published December 6, 2017 in the open-access journal PLOS ONE by Terra Arnason from the University of Saskatchewan, Canada, and colleagues.

Previous studies have shown that metformin has some antiproliferative activity against multiple types of cancer cells. Moreover, clinical meta-analysis studies on cancer patients who already take metformin to treat diabetes have hinted that the drug may boost their survival and prevent the emergence of new tumors.

Arnason and colleagues probed the effect of metformin on the widely studied cell line MCF7. Metformin, they found, had an antiproliferative effect on MCF7, including cells that were resistant to the common chemotherapeutic Doxorubicin. When cells were pretreated with metformin, the development of drug resistance was prevented or delayed. In addition, experiments conducted in both cell cultures and mouse models of aggressive breast cancer revealed that metformin reversed protein markers associated with MDR after its onset.

These findings establish that metformin has the potential to both reverse MDR in cell lines and prevent its onset. Future research will need to extend the timeline of the study to follow for many months and determine if the effect of is permanent or short-lived.

Explore further: Metformin use does not increase prostate cancer survival

More information: Gerald Davies et al, Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer, PLOS ONE (2017). DOI: 10.1371/journal.pone.0187191

Related Stories

Metformin use does not increase prostate cancer survival

April 11, 2017
(HealthDay)—Metformin use in combination with docetaxel chemotherapy does not significantly improve survival in patients with diabetes and metastatic castration-resistant prostate cancer, according to a study published ...

Prevalence of metformin use 0.7 percent in prediabetes

April 7, 2017
(HealthDay)—For U.S. adults with prediabetes, the prevalence of metformin use is 0.7 percent, according to a study published online April 3 in Diabetes Care.

Metformin therapeutic as post-ischemic conditioning agent

June 29, 2017
(HealthDay)—Metformin has therapeutic potential as a post-ischemic conditioning agent, according to a study published online June 23 in Cardiovascular Therapeutics.

Metformin use linked to less vitamin B12 measurement

February 17, 2017
(HealthDay)—Long-term metformin use is associated with lower serum vitamin B12 concentration, although metformin users are less likely to receive vitamin B12 testing, according to a study published online Feb. 9 in the ...

Common diabetes drug may help treat ovarian cancer

December 3, 2012
A new study suggests that the common diabetes medication metformin may be considered for use in the prevention or treatment of ovarian cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer ...

Metformin confers anti-tumor immunity by reactivating exhausted CD8T lymphocytes

February 24, 2016
Anti-cancer effect of tumor infiltrating CD8+T lymphocyte (CD8TIL) is suppressed by interaction between immune-checkpoint molecules such as PD-1 and CTLA-4 expressed on CD8TIL and their ligands expressed on cancer cells, ...

Recommended for you

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.